230 related articles for article (PubMed ID: 23837261)
1. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
2. Pharmaceuticals and medical devices: business practices. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840
[No Abstract] [Full Text] [Related]
3. Glaxo agrees to post results of drug trials on web site.
Harris G
N Y Times Web; 2004 Aug; ():C4. PubMed ID: 15540364
[No Abstract] [Full Text] [Related]
4. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
Vedantam S
Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
[No Abstract] [Full Text] [Related]
5. Congress may force drug firms to reveal clinical trial data.
Check E
Nature; 2004 Sep; 431(7006):232. PubMed ID: 15371992
[No Abstract] [Full Text] [Related]
6. Drug-company data vaults to be opened.
Cressey D
Nature; 2013 Mar; 495(7442):419-20. PubMed ID: 23538802
[No Abstract] [Full Text] [Related]
7. Expose your clinical thinking.
Nat Biotechnol; 2004 Aug; 22(8):927. PubMed ID: 15286628
[No Abstract] [Full Text] [Related]
8. Drug companies, doctors and disclosures.
Tuorto S; Chan MK; Adusumilli PS
Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772
[No Abstract] [Full Text] [Related]
9. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
10. Drug trade bodies rally patient groups to deflect calls for full trial data.
O'Dowd A
BMJ; 2013 Jul; 347():f4702. PubMed ID: 23882001
[No Abstract] [Full Text] [Related]
11. Despite vow, drug makers still withhold data.
Berenson A
N Y Times Web; 2005 May; ():A1, C3. PubMed ID: 15952254
[No Abstract] [Full Text] [Related]
12. Out in the open.
Nat Biotechnol; 2005 Feb; 23(2):153. PubMed ID: 15696130
[No Abstract] [Full Text] [Related]
13. NICE is urged to make drug companies supply all trial data.
O'Dowd A
BMJ; 2012 Dec; 345():e8294. PubMed ID: 23223692
[No Abstract] [Full Text] [Related]
14. Disclosing clinical trial results: publicity, significance and independence.
Liao SM; Sheehan M; Clarke S
Am J Bioeth; 2009 Aug; 9(8):W3-5. PubMed ID: 19998144
[No Abstract] [Full Text] [Related]
15. Making available information from studies sponsored by the pharmaceutical industry: some current practices.
O'Kelly M; Julious SA; Pyke S; Day S; Todd S; Seldrup J; Matcham J
Pharm Stat; 2011; 10(1):60-9. PubMed ID: 21275036
[TBL] [Abstract][Full Text] [Related]
16. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
James JS
AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
[TBL] [Abstract][Full Text] [Related]
17. Health related claims, the market for information, and the first amendment.
Beales JH
Health Matrix Clevel; 2011; 21(1):7-30. PubMed ID: 21847896
[No Abstract] [Full Text] [Related]
18. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
19. Company stock prices before and after public announcements related to oncology drugs.
Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
[TBL] [Abstract][Full Text] [Related]
20. Regulatory transparency: social, technical, and ethical aspects of clinical trial data access.
Sousa VD; Silveira D
Rev Panam Salud Publica; 2015 Jun; 37(6):430-4. PubMed ID: 26245179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
